Highly variable pH effects on the interaction of diclofenac and indomethacin with human UDP-glucuronosyltransferases

Toxicology in Vitro

Volumn 26, Issue 8, 2012, Pages 1286-1293

  Zhang, Hongbo ^a   Soikkeli, Anne ^a   Tolonen, Ari ^b,c   Rousu, Timo ^b,d   Hirvonen, Jouni ^a   Finel, Moshe ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Novamass Ltd   (Finland)

^c Admescope Ltd   (Finland)

^d UNIVERSITY OF OULU   (Finland)

Author keywords

Acyl migration; Diclofenac; Indomethacin; UDP glucuronosyltransferase

Indexed keywords

DICLOFENAC; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 2A; GLUCURONOSYLTRANSFERASE 2B; GLUCURONOSYLTRANSFERASE 2B15; GLUCURONOSYLTRANSFERASE 2B7; GLUCURONOSYLTRANSFERASE 2B71; HYMECROMONE; INDOMETACIN; UNCLASSIFIED DRUG; 1 NAPHTHOL; 1-NAPHTHOL; 4-METHYLUMBELLIFERONE; ANTIINFLAMMATORY AGENT; DRUG DERIVATIVE; GLUCURONIDE; NAPHTHOL DERIVATIVE;

ARTICLE; CATALYSIS; DRUG GLUCURONIDATION; DRUG INTERACTION; DRUG MECHANISM; ENZYME INHIBITION; FLUORESCENCE; HUMAN; IC50; IN VITRO STUDY; KINETICS; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; PH; PROTEIN EXPRESSION; ULTRAVIOLET RADIATION; COMPARATIVE STUDY; IC 50; METABOLISM;

ANTI-INFLAMMATORY AGENTS; DICLOFENAC; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; HYDROGEN-ION CONCENTRATION; HYMECROMONE; INDOMETHACIN; INHIBITORY CONCENTRATION 50; NAPHTHOLS;

EID: 84856247392     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2012.01.005     Document Type: Article

References (28)

1. Basu, N.K., Ciotti, M., Hwang, M.S., Kole, L., Mitra, P.S., Cho, J.W., Owens, I.S., Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J. Biol. Chem. 279 (2004), 1429–1441.
2. Bushey, R.T., Chen, G., Blevins-Primeau, A.S., Krzeminski, J., Amin, S., Lazarus, P., Characterization of UDP-glucuronosyltransferase 2A1 (UGT2A1) variants and their potential role in tobacco carcinogenesis. Pharmacogenet. Genomics 21 (2011), 55–65.
3. Chang, J.H., Yoo, P., Lee, T., Klopf, W., Takao, D., The role of pH in the glucuronidation of raloxifene, mycophenolic acid and ezetimibe. Mol. Pharm. 6 (2009), 1216–1227.
4. Court, M.H., Zhang, X., Ding, X., Yee, K.K., Hesse, L.M., Finel, M., Quantitative distribution of mRNAs encoding the 19 human UDP-glucuronosyltransferase enzymes in 26 adult and 3 fetal tissues. Xenobiotica 42 (2012), 266–277.
5. Dubois, S.G., Beaulieu, M., Lévesque, E., Hum, D.W., Bélanger, A., Alteration of human UDPglucuronosyltransferase UGT2B17 regio-specificity by a single amino acid substitution. J. Mol. Biol. 289 (1999), 29–39.
6. Faed, E.M., Properties of acyl glucuronides: implications for studies of the pharmacokinetics and metabolism of acidic drugs. Drug Metab. Rev. 15 (1984), 1213–1249.
7. Itäaho, K., Mackenzie, P., Ikushiro, S.I., Miners, J., Finel, M., The configuration of the 17-hydroxy group variably influences the glucuronidation of {beta}-estradiol and epiestradiol by human UDP-glucuronosyltransferases. Drug Metab. Dispos. 36 (2008), 2307–2315.
8. Itäaho, K., Court, M.H., Uutela, P., Kostiainen, R., Radominska-Pandya, A., Finel, M., Dopamine is a low-affinity and high-specificity substrate for the human UDP-glucuronosyltransferase 1A10. Drug Metab. Dispos. 37 (2009), 768–775.
9. Kuehl, G.E., Lampe, J.W., Potter, J.D., Bigler, J., Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab. Dispos. 33 (2005), 1027–1035.
10. Kurkela, M., Patana, A.S., Mackenzie, P.I., Court, M.H., Tate, C.G., Hirvonen, J., Goldman, A., Finel, M., Interactions with other human UDP-glucuronosyltransferases attenuate the consequences of the Y485D mutation on the activity and substrate affinity of UGT1A6. Pharmacogenet. Genomics 17 (2007), 115–126.
11. Luukkanen, L., Taskinen, J., Kurkela, M., Kostiainen, R., Hirvonen, J., Finel, M., Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyltransferases. Drug Metab. Dispos. 33 (2005), 1017–1026.
12. Mackenzie, P.I., Bock, K.W., Burchell, B., Guillemette, C., Ikushiro, S., Iyanagi, T., Miners, J.O., Owens, I.S., Nebert, D.W., Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet. Genomics 15 (2005), 677–685.
13. Mano, Y., Usui, T., Kamimura, H., Contribution of UDP-glucuronosyltransferases 1A9 and 2B7 to the glucuronidation of indomethacin in the human liver. Eur. J. Clin. Pharmacol. 63 (2007), 289–296.
14. Ohno, S., Nakajin, S., Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab. Dispos. 37 (2009), 32–40.
15. Ritter, J.K., Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions. Chem. Biol. Interact. 129 (2000), 171–193.
16. Shipkova, M., Armstrong, V.W., Oellerich, M., Wieland, E., Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther. Drug Monit. 25 (2003), 1–16.
17. Sneitz, N., Court, M.H., Zhang, X., Laajanen, K., Yee, K.K., Dalton, P., Ding, X., Finel, M., Human UDP-glucuronosyltransferase UGT2A2: cDNA construction, expression, and functional characterization in comparison with UGT2A1 and UGT2A. Pharmacogenet. Genomics 19 (2009), 923–934.
18. Soikkeli, A., Kurkela, M., Hirvonen, J., Yliperttula, M., Finel, M., Fluorescence-based high-throughput screening assay for drug interactions with UGT1A6. Assay Drug Dev. Technol. 9 (2011), 496–502.
19. Spahn-Langguth, H., Benet, L.Z., Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism?. Drug Metab. Rev. 24 (1992), 5–47.
20. Tang, W., The metabolism of diclofenac – enzymology and toxicology perspectives. Curr. Drug Metab. 4 (2003), 319–329.
21. Uchaipichat, V., Mackenzie, P.I., Guo, X.-H., Gardner-Stephen, D., Galetin, A., Houston, J.B., Miners, J.O., Human UDP-glucuronosyltransferases: Isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab. Dispos. 32 (2004), 413–423.
22. Vree, T.B., van den Biggelaar-Martea, M., Verwey-van Wissen, C.P., Determination of indomethacin, its metabolites and their glucuronides in human plasma and urine by means of direct gradient high-performance liquid chromatographic analysis. Preliminary pharmacokinetics and effect of probenecid. J. Chromatogr. 616 (1993), 271–282.
23. Walker, A.M., Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal antiinflammatory drugs. Arthritis Rheum. 40 (1997), 201–208.
24. Walker, G.S., Atherton, J., Bauman, J., Kohl, C., Lam, W., Reily, M., Lou, Z., Mutlib, A., Determination of degradation pathways and kinetics of acyl glucuronides by NMR spectroscopy. Chem. Res. Toxicol. 20 (2007), 876–886.
25. Wells, P.G., Mackenzie, P.I., Chowdhury, J.R., Guillemette, C., Gregory, P.A., Ishii, Y., Hansen, A.J., Kessler, F.K., Kim, P.M., Chowdhury, N.R., Ritter, J.K., Glucuronidation and the UDP-glucuronosyltransferases in health and disease. Drug Metab. Dispos. 32 (2004), 281–290.
26. Wilson 3rd, W., Pardo-Manuel de Villena, F., Lyn-Cook, B.D., Chatterjee, P.K., Bell, T.A., Detwiler, D.A., Gilmore, R.C., Valladeras, I.C., Wright, C.C., Threadgill, D.W., Grant, D.J., 2004. Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15. Genomics 84, 707–714.
27. Zhang, H., Tolonen, A., Rousu, T., Hirvonen, J., Finel, M., Effects of cell differentiation and assay conditions on the UDP-glucuronosyltransferases activity in Caco-2 cells. Drug Metab. Dispos. 39 (2011), 456–464.
28. Zhu, L., Ge, G., Zhang, H., Liu, H., He, G., Liang, S., Zhang, Y., Fang, Z., Dong, P., Finel, M., Yang, L., 2012. Characterization of hepatic and intestinal glucuronidation of magnolol: application of the RAF approach to decipher the contributions of multiple UGT isoforms. Drug Metab. Dispos., in press, doi:10.1124/dmd.111.042192.